Maintain adequate nutrition: Ensure sufficient carbohydrate, protein, and overall caloric intake to support research protocol Assess joint and neurological symptoms: Monitor for swelling, carpal tunnel symptoms, or other adverse effects regularly Periodic biomarker assessment: Re-check glucose, lipids, and metabolic markers at mid-point and end of protocol Plan discontinuation protocol: Gradually reduce dosing over 1-2 weeks at research conclusion rather than abrupt cessation Post-research assessment: Verify that all parameters (glucose, lipids, metrics, symptoms) return to baseline after discontinuation Conclusion IGF-1 LR3 has a generally favourable safety profile when used in research with appropriate doses, duration, and monitoring protocols
Claim: it lessens inflammation. Truth: not really
The information in this article is for educational purposes only and should not be considered medical advice
The long-term effects of metformin on patients with type 2 diabetic kidney disease
No fussy sweeteners, colorants, or synthetic fillers
Brain fog: Difficulty concentrating or thinking clearly